Good time to highlight my impeccable flight etiquette:→ I have snacks (protein bars, water, edamame)→ Tech kit for emergency charges, cables, headphones→ I won't have to piss, but I will get up and stretch around hour 5. Just some calf raises and toe touches.→ I will neatly eat and throw away my in-flight meal (I'll also wake you for yours if requested)→ I only take up one seat→ I tip all flight attendants 20% of flight, as is commiserate of a US-based serviceBonus:If you want extra airline snacks I know ho ...

Core Viewpoint - Burcon NutraScience Corporation is set to showcase its innovative Chipotle Black Bean Protein Hummus at the IFT FIRST Annual Event & Expo, highlighting its advancements in plant-based protein technology [1][6]. Group 1: Product Innovation - The Chipotle Black Bean Protein Hummus is crafted using Burcon's proprietary triple blend of Peazazz®C pea protein, Puratein®C canola protein, and Solatein™ sunflower protein, resulting in a dip that is both flavorful and nutritious [6][8]. - Burcon's plant-based proteins boast over 90% purity, neutral flavor, and smooth mouthfeel, making them suitable for various food applications [6][9]. Group 2: Event Details - The IFT FIRST event will take place in Chicago from July 13-16, 2025, where Burcon will be located at booth S4066 [1][6]. - Attendees will have the opportunity to sample the Chipotle Black Bean Protein Hummus during a special tasting event on July 14 and 15, from 11:00 AM to 1:00 PM [7][9]. Group 3: Company Background - Burcon NutraScience is recognized as a global leader in high-performance plant-based proteins, with a strong commitment to sustainability and innovation in the food and beverage industry [11]. - The company holds an extensive patent portfolio covering novel proteins derived from various plant sources, positioning itself as a key player in the growing plant-based market [11].

Core Viewpoint - IGI Therapeutics and AbbVie have entered into an exclusive licensing agreement for ISB 2001, a novel trispecific T-cell engager targeting multiple myeloma, which is currently in Phase 1 clinical trials [1][2]. Company Overview - IGI Therapeutics is a clinical-stage biotechnology company focused on developing innovative biologics in oncology, utilizing its proprietary BEAT® technology platform to create first-in-class multispecific therapies [7]. - AbbVie is a global biopharmaceutical company dedicated to discovering and delivering innovative medicines across various therapeutic areas, including oncology [8]. Product Details - ISB 2001 is designed to target BCMA and CD38 on myeloma cells and CD3 on T cells, aiming to improve safety and efficacy compared to first-generation bispecific antibodies [3]. - The drug has shown a sustained overall response rate (ORR) of 79% and a complete/stringent complete response (CR/sCR) rate of 30% in a heavily pretreated patient population [3]. Licensing Agreement - Under the agreement, AbbVie will have exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China [2]. - IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales [2]. Regulatory Designations - ISB 2001 received Orphan Drug Designation from the U.S. FDA in July 2023 and Fast Track Designation for treating relapsed/refractory myeloma patients in May 2025 [4]. BEAT® Platform - The BEAT® platform enables the development of next-generation immune cell engagers with enhanced stability and function, addressing limitations of traditional bispecific antibody production [5]. - Key features include multispecific versatility, optimized engineering for precise modulation, and robust manufacturability [5].

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases."Multispecifics ...

Core Insights - OraSure Technologies, Inc. has launched the HEMAcollect™ ● PROTEIN product aimed at enhancing proteomic research through improved sample collection and preservation [1][2] - The HEMAcollect™ ● PROTEIN is an evacuated blood collection tube designed to stabilize plasma proteins for up to seven days, addressing limitations of traditional blood collection methods [1][2] - The product is expected to provide operational and financial efficiencies for proteomic researchers, facilitating high-quality data generation [1] Product Features - The HEMAcollect™ ● PROTEIN BCT utilizes ProteoPrecision™ technology to minimize hemolysis and platelet activation, ensuring sample integrity [2] - It is compatible with various proteomic technologies, including mass spectrometry and immunoassays, making it versatile for different research applications [2] Company Overview - OraSure Technologies focuses on transforming healthcare through innovative diagnostic tests and sample management solutions, serving a wide range of customers including clinical laboratories and pharmaceutical companies [4] - DNA Genotek, a subsidiary of OraSure, specializes in developing products that optimize sample collection and performance for high-quality biological samples [5]

GREELEY, Colo., July 09, 2025 (GLOBE NEWSWIRE) -- Pilgrim’s Pride Corporation (NASDAQ: PPC) announced today that it will release its second quarter 2025 financial results after the U.S. market closes on Wednesday, July 30. The company’s executives will review the results on a conference call and webcast on Thursday, July 31, 2025, at 7:00 a.m. MT (9:00 a.m. ET). Prepared remarks regarding the company’s financial and operational results will be followed by a question and answer period with the Pilgrim’s exec ...

Industry Overview - The agriculture industry is undergoing a significant transformation driven by advanced technologies and innovations, addressing the urgent need for sustainable and efficient farming practices due to global population growth and climate change [2][3] - Agricultural technology (AgTech) and food innovation are pivotal in revolutionizing food production, enhancing productivity, and reducing environmental impact [2][3] AgTech Innovations - AgTech is reshaping food production, processing, and distribution through advancements in artificial intelligence (AI), biotechnology, and automation, leading to smarter and more sustainable agriculture [3] - Technologies such as precision farming, lab-grown meat, and plant-based alternatives are at the forefront of this transformation, enabling farmers to optimize operations and reduce resource waste [3][5] Protein Market Transformation - The global protein market is shifting towards healthier and more sustainable alternatives, including plant-based proteins and lab-grown meat, driven by health-conscious consumers [4] - Companies like Ingredion Incorporated are investing in plant-based ingredients to meet the rising global demand for sustainable protein solutions [4] Supply Chain Enhancements - Emerging technologies like blockchain and the Internet of Things (IoT) are improving food traceability and safety standards while minimizing waste in logistics and distribution [5] - Automation in food processing and packaging is enabling companies to deliver fresher products more efficiently and reduce operational costs [5] Investment Opportunities - Companies adopting advanced technologies are gaining a competitive edge, with top-performing stocks in AgTech and food innovation presenting compelling investment opportunities [6] - Industry leaders such as Beyond Meat, Hormel Foods, and Tyson Foods are leveraging AgTech to enhance growth and competitiveness [6] Beyond Meat Initiatives - Beyond Meat is focused on redefining protein production through innovative plant-based meats that replicate traditional animal products, addressing climate change and public health challenges [8] - The company is expanding its global footprint and investing in sustainable product development and supply chain transformation [11] Hormel Foods Strategies - Hormel Foods is utilizing digital technologies and AgTech solutions to enhance operational efficiency and food production standards, including a $1.7 million investment in regenerative agriculture [11][13] - The company is expanding its innovation pipeline with a focus on alternative protein development through partnerships, such as with The Better Meat Co. [12] Tyson Foods Transformation - Tyson Foods is investing in agricultural technology and food innovation to support sustainable protein production and digital transformation [14] - The company is enhancing operational efficiency through automation and logistics improvements, aiming for $200 million in annual savings by 2030 [16]

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to h ...

Company Overview - BellRing Brands, Inc. (NYSE: BRBR) is a fast-growing consumer brands business focused on the convenient nutrition category, with brands such as Premier Protein and Dymatize [3] - The company aims to change lives with good energy and believes nutrition is essential for a healthy world, producing products with top nutritional profiles and flavors [3] - BellRing's products are distributed in over 90 countries across various channels including club, mass, food, eCommerce, specialty, drug, and convenience [3] Upcoming Financial Events - BellRing Brands will hold a conference call on August 5, 2025, at 9:00 a.m. EDT to discuss its financial results for the third quarter of fiscal year 2025 and provide an outlook for the fiscal year [1] - The financial results for the third quarter will be released after market close on August 4, 2025 [1] - The call will feature participation from Darcy H. Davenport, President and CEO, and Paul A. Rode, CFO [1]

For purposes of public disclosure, including this and future similar events, Sysco uses the investor relations section of its website, found at investors.sysco.com, as the primary channel for publishing key information to its investors, some of which may contain material and previously non-public information. About Sysco Sysco is the global leader in selling, marketing and distributing food and related products to customers who prepare meals away from home. This includes restaurants, healthcare and educatio ...